Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK 831 in Healthy Adult Asian Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs TAK 831 (Primary)
- Indications Ataxia; Friedreich's ataxia; Schizophrenia
- Focus Adverse reactions
- Sponsors Takeda
- 19 Jun 2019 Status changed from active, no longer recruiting to completed.
- 10 Jun 2019 Planned End Date changed from 13 Jun 2019 to 19 Jun 2019.
- 10 Jun 2019 Planned primary completion date changed from 13 Jun 2019 to 19 Jun 2019.